Archives
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
- 2021-12
- 2021-11
- 2021-10
- 2021-09
- 2021-08
- 2021-07
- 2021-06
- 2021-05
- 2021-04
- 2021-03
- 2021-02
- 2021-01
- 2020-12
- 2020-11
- 2020-10
- 2020-09
- 2020-08
- 2020-07
- 2020-06
- 2020-05
- 2020-04
- 2020-03
- 2020-02
- 2020-01
- 2019-12
- 2019-11
- 2019-10
- 2019-09
- 2019-08
- 2019-07
- 2019-06
- 2018-07
-
Luciferase Reporter Assay Kit ACE inhibition is often though
2023-10-13

ACE inhibition is often thought to play a central role in the mechanisms of blood pressure reduction in vivo, and most ACE inhibitory (ACEi) peptides were characterized based on in vitro ACE inhibition. A relationship between in vitro ACE inhibition and antihypertensive activity, however, is not app
-
This study does have several limitations mainly related to
2023-10-13

This study does have several limitations, mainly related to the DMSO vehicle. While DMSO is a known anti-inflammatory mediator,5, 12 it has been shown to upregulate ALOX5, which was not seen in this study (as we are likely underpowered to detect this difference). A manifestation of this anti-inflamm
-
br Conclusion There have been
2023-10-13

Conclusion There have been multiple clinical trials and pre-clinical studies that have tested the utility of 5ARIs in treating prostate disease, as summarized in Fig. 1. Inhibiting androgen action through the use of finasteride and dutasteride has been established as a valuable resource for physi
-
Small kinase inhibitors have been developed to block AXL
2023-10-13

Small kinase inhibitors have been developed to block AXL by interacting with the kinase cytoplasmic ATP binding site. Up to date, no AXL selective kinase inhibitors are marketed. As depicted in , some marketed kinase inhibitors such as Bosutinib and Cabozantinib or kinase inhibitors in clinical pha
-
br Materials and methods br Results br Discussion The succes
2023-10-13

Materials and methods Results Discussion The success of CAR-T cell therapy is based on two major facts: one is that cancer cells express tumor-associated antigens (TAAs) on their surface that can be detected by the human immune system; the other is that the CAR molecules target these TAAs o
-
By performing knockdown of AXL once HER cancer cells have
2023-10-13

By performing knockdown of AXL once HER2+ cancer Netarsudil australia have achieved lung colonization, we demonstrated that AXL contributes to the establishment of macrometastases. While inhibition of AXL impairs the efficiency of metastasis, the later finding has major clinical implications since
-
br Introduction The process of
2023-10-13

Introduction The process of mitosis is highly complex and tightly regulated. This phase of the Cytidine 5-triphosphate resulted in two identical daughter cells. The aurora kinases (aurora A, B, and C) are a family of three highly homologous serine-threonine protein kinases that play a key role i
-
Investigating these possibilities will illuminate whether ce
2023-10-12

Investigating these possibilities will illuminate whether Fluorescein-12-dUTP possess mechanisms to differentially detect ACLY-generated versus ACSS2-generated acetyl-CoA as well as define the functional relationship between histone acetylation levels and cellular functions and phenotypes. Given th
-
Aminoglutethimide first generation aromatase inhibitor has b
2023-10-12

Aminoglutethimide, first generation aromatase inhibitor, has been tried as an antiepileptic drug in combination with other standard drugs (Aguilar et al., 1961). Letrozole is a third generation reversible non-steroidal aromatase inhibitor, approved by US-FDA, for the treatment of postmenopausal wome
-
br AR signals and chemosensitivity in urothelial cancer
2023-10-12

AR signals and chemosensitivity in urothelial cancer A significant amount of patients with urothelial cancer fail to respond to cisplatin-based systemic chemotherapy, although it remains the mainstay of successful management of advanced disease. However, underlying mechanisms for chemoresistance
-
br Material and methods br Results br Discussion Aminopeptid
2023-10-12

Material and methods Results Discussion Aminopeptidase N is a transmembrane protease present in a wide variety of human tissues and cell types (endothelial, epithelial, fibroblast, leukocyte). APN expression is dysregulated in inflammatory diseases as well as in solid and hematologic tumors
-
Recently rather than predicting categorical
2023-10-12

Recently, rather than predicting categorical variables as in classification, several studies begin to estimate continuous clinical variables from pentylenetetrazol images. Therefore, instead of classify a subject into binary or multiple pre-determined categories or stages of the disease, regression
-
Interestingly all of the ROS
2023-10-12

Interestingly, all of the ROS1 rearrangements share a constant breakpoint in ROS1 and the fusion product contain the kinase domain resulting in aberrant ROS1 expression with constitutive kinase activity. Intrachromosomal deletions and interchromosomal translocations have demonstrated the existence o
-
The PAS domains of AHR consist of two regions PAS
2023-10-12

The PAS domains of AHR consist of two regions, PAS-A and PAS-B, which function as interfaces for dimerization with ARNT and for ligand binding, respectively [14]. Although both the bHLH and the PAS-A domains have been shown to be involved in dimerization with ARNT, a recent report suggests that only
-
br Materials and methods br Results br
2023-10-12

Materials and methods Results Discussion Several major signaling and developmental pathways (e.g. EGFR, ALK, KRAS, TGFβ, Notch and Wnt/β-catenin) have been shown to be involved in lung carcinogenesis and they are being exploited as targets of the non-small cell lung cancer therapy (for revi
15614 records 273/1041 page Previous Next First page 上5页 271272273274275 下5页 Last page